MEDA: Dymista Approved in Europe

  MEDA: Dymista Approved in Europe

Business Wire

GÖTEBORG, Sweden -- January 24, 2013

Regulatory News:


Dymista has received medical approval in Europe via the decentralized
registration procedure. Dymista is approved for the treatment of seasonal and
perennial allergic rhinitis. National registration processes, including
negotiations regarding pricing and reimbursement, will now follow in each
country prior to launch. Launches are anticipated in 2013 in several

"Patients in Europe that suffer from allergic rhinitis will soon have access
to a better treatment option than the current standard therapy. The faster and
more complete effect offers significant benefit to the growing numbers of
patients suffering from this difficult and inhibiting disease", said Anders
Lönner, CEO of Meda AB.

About Dymista

Dymista is a novel nasal formulation of azelastine and fluticasone. The
efficacy and safety of Dymista has been documented in several studies with
more than 4,000 patients, including a long-term safety study with more than
600 patients. Dymista has consistently showed faster and more complete symptom
relief than standard treatment. Dymista has been available in the US since
September 2012.

MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in 120 countries worldwide and the company is represented by
its own organizations in 50 countries. The Meda share is listed under Large
Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit

Forward-looking statements

This press release is not an offer to sell or a solicitation to buy shares in
Meda. This press release also contains certain forward-looking statements with
respect to certain future events and Meda’s potential financial performance.
These forward-looking statements can be identified by the fact that they do
not relate only to historical or current facts, and may sometimes include
words such as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”,
“intend”, “plan”, “forecast”, “believe” or other words of similar meaning.
These forward looking statements reflect the current expectations on future
events of the management at the time such statements are made, but are made
subject to a number of risks and uncertainties. In the event such risks or
uncertainties materialize, Meda’s results could be materially affected. The
risks and uncertainties include, but are not limited to, risks associated with
the inherent uncertainty of pharmaceutical research and product development,
manufacturing and commercialization, the impact of competitive products,
patents, legal challenges, government regulation and approval, Meda’s ability
to secure new products for commercialization and/or development and other
risks and uncertainties detailed from time to time in Meda AB’s interim or
annual reports, prospectuses or press releases. Listeners and readers are
cautioned that no forward-looking statement is a guarantee of future
performance and that actual result could differ materially from those
contained in the forward-looking statements. Meda does not intend, nor
undertakes, to update any such forward looking statements.

This information was brought to you by Cision


Anders Larnholt
Vice President Corporate Development & IR
ph: +46 709-458 878
Paula Treutiger,
Investor Relations
ph: +46 733-666 599
Press spacebar to pause and continue. Press esc to stop.